coherent
发表于 2025-3-21 17:40:23
书目名称Biopharma in China影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0188311<br><br> <br><br>书目名称Biopharma in China读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0188311<br><br> <br><br>
物质
发表于 2025-3-21 22:18:51
http://reply.papertrans.cn/19/1884/188311/188311_2.png
否决
发表于 2025-3-22 01:04:41
http://reply.papertrans.cn/19/1884/188311/188311_3.png
傻
发表于 2025-3-22 08:09:32
Innovation in the Chinese Biopharma Sector: From Me-too to First-in-Class,decade old, but a momentous shift has occurred already. By now China’s R&D has come a long way, moving away from generic drugs to the latest technologies. Starting in the early 2000s, a first wave of new generation innovative pharma companies formed in China. As scientific research and core R&D howe
Reservation
发表于 2025-3-22 09:06:51
The Art of the Biopharma Deal: The China Angle,tors. Anybody who wants to raise money from Chinese investors or strike a partnering or cooperation deal with Chinese companies however, needs to understand what investors or Chinese pharma companies are looking for. And because of the vast differences and needs of the Chinese healthcare and pharmac
inchoate
发表于 2025-3-22 14:00:30
End of the First Cycle, 2022 and Beyond: A Drastic Reset, Increased Challenges But Also New Opportutween the period 2018–2022 we witnessed a growth phase, catalyzed by even more funding and new IPO channels in Hong Kong and Shanghai. 2022 saw the start of a reset phase characterized by a drastic market correction, in line with global biotech trends. Companies and healthcare funds alike need to re
infantile
发表于 2025-3-22 17:34:40
http://reply.papertrans.cn/19/1884/188311/188311_7.png
游行
发表于 2025-3-23 00:48:39
Springer Series in Optical Sciencesvation was non-existent. The ‘Healthy China 2030’ initiative however, changed all that. Over the last decade China has made significant strides in upgrading and updating all aspects of the healthcare system. A key pillar in these upgrades were the changes being made in its legal and regulatory frame
外来
发表于 2025-3-23 01:41:13
https://doi.org/10.1007/978-3-540-38950-7ive domestic growth in the pharma and biotech space. With the largest population in the world and with little access to the latest innovative medicines, China provided huge market opportunities. Regulatory reforms made approval of new drugs much easier, which led to venture capitalists eying the Chi
宪法没有
发表于 2025-3-23 06:56:18
http://reply.papertrans.cn/19/1884/188311/188311_10.png